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Introduction: Developing orphan drugs is challenging because of their severity and the requisite for effective
drugs. The small number of patients does not allow conducting adequately powered randomized controlled trials
(RCTs). There is a need to develop high quality, ethically investigated, and appropriately authorized medicines,
without subjecting patients to unnecessary trials.
Aims and Objectives: The main aim is to develop generalizable framework for choosing the best-performing
drug/endpoint/design combinations in orphan drug development using an in silico modeling and trial simulation
approach. The two main objectives were (i) to provide a global strategy for each disease to identify the most
relevant drugs to be evaluated in specific patients during phase III RCTs, (ii) and select the best design for each drug
to be used in future RCTs.
Methodological approach: In silico phase III RCT simulation will be used to find the optimal trial design and was
carried out in two steps: (i) statistical analysis of available clinical databases and (ii) integrative modeling that combines
mathematical models for diseases with pharmacokinetic-pharmacodynamics models for the selected drug candidates.
Conclusion: There is a need to speed up the process of orphan drug development, develop new methods for
translational research and personalized medicine, and contribute to European Medicines Agency guidelines. The
approach presented here offers many perspectives in clinical trial conception.
Keywords: Rare diseases, Drug development, Integrative modeling, Clinical trial simulationIntroduction
The European Commission on Public Health defines
rare diseases as “life-threatening or chronically debilitat-
ing diseases which are of such a low prevalence that spe-
cial combined efforts are needed to address them” [1].
The term low prevalence is defined as less than 1 in
2,000 people affected. It has been estimated that there
are between 6,000 and 8,000 rare diseases that may
affect up to 30 million people in the European Union
alone. About 80% of these rare diseases have an identi-
fied genetic origin involving one or several genes or
chromosomal abnormalities [2]. The others are caused* Correspondence: pn@upcl.univ-lyon1.fr
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unless otherwise stated.by infections (bacterial or viral), or allergies, or are due to
degenerative, proliferative or teratogenic (chemicals, radia-
tions, etc.) causes. Some rare diseases are also caused by a
combination of genetic and environmental factors [2].
Rare diseases include a wide range of disorders and symp-
toms across diseases and patients suffering from the same
disease. Therefore, it is impossible to develop public
health policies specific to each rare disease. A global ap-
proach to rare diseases is required to create policies on
scientific and biomedical research, drug research and de-
velopment, industry policies, training, social benefits,
hospitalization, and outpatient treatment.
Orphan drugs are developed to treat rare diseases, often
known as orphan diseases (Table 1). Orphan drugs follow
the same regulatory development path as other pharma-
ceutical products, with studies focusing on pharmacokin-
etics, pharmacodynamics, dosing, stability, safety, andtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Table 1 Orphan and non-orphan medicine (adapted from Spilker B)
Orphan medicine Non-orphan medicine
Used in a limited patient population Used in a large patient population
Often used by only a few specialists Generally used by a wide variety or number of physicians
The manufacturer often loses money The manufacturer is more likely to make money
May require less patient exposure to obtain marketing authorization Usually requires a standard quantity of data before marketing authorization
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(RCTs) may be difficult to conduct due to the small num-
ber of potential participants. Drug manufacturers and
regulatory agencies have traditionally been skeptical of
small clinical trials, mainly because of their low statistical
power and lack of transposability. New approaches to
protocol design are currently required for trials with small
sample sizes that can assess the potential therapeutic effi-
cacy of drugs, biological products, medical devices, and
other medical interventions. We propose here a strategy in
order to optimize the clinical drug development (designing
of phase III trials) in the field of rare diseases.
The standard approach to clinical drug evaluation in humans
When evaluating the intended effects of drugs, well-
conducted RCTs have been widely accepted as the scien-
tific standard [3]. Randomization is the key component
of RCTs. It allows focusing only on the outcome variable
(s) in different treatment groups when assessing an un-
biased treatment effect. As proper randomization con-
firms that the treatment groups differ on all known and
unknown prognostic factors only by chance, probability
theory can be used to make interpretations about the
treatment effect in the population under study (confidence
intervals, significance, etc.) and it removes potential selec-
tion bias [4].
Randomization does not ensure equality for all prognos-
tic factors in the treatment groups, especially with small
sample sizes, but it does ensure that confidence intervals
and p-values are validated using probability theory [5].
Occasionally randomized comparison of treatments may
not be considered feasible due to ethical, economical and
other limitations related to the rareness of the disease [6].
RCTs usually exclude particular groups of patients (be-
cause of age, other drug usage, or noncompliance). They
are mainly conducted under strict, protocol-driven condi-
tions and experimental drugs are generally taken for
shorter periods than drugs used in clinical practice. The
main alternatives are observational studies. Their validity
for assessing intended effects of therapies has long been
debated and remains controversial [7-9].
Limitations of using the standard approach in rare
diseases
The small numbers of patients, who are spread out over
a wide geographical area make it difficult to carry outtraditional clinical trials (i.e. RCTs in parallel groups) with
enough power. There is a need for individually-tailored
therapies and the inclusion of specific populations. It is
also a useful approach to favor investigators who are spe-
cialized in the disease, use patient inclusion criteria that
are as inclusive as possible, measure the treatment effect
with an endpoint that is as standard as possible, and
include patient associations and public institutions when
preparing the trial. For the same disease, there may be sev-
eral new treatments to evaluate. The total number of clin-
ical trials is limited, so a choice must be made to favor
the evaluation of one treatment over others. If we want to
evaluate a treatment strategy while carrying out comple-
mentary paraclinical evaluation (i.e. a theranostic ap-
proach), we have to choose one or a few limited strategies
to compare to the conventional strategy because of the
large number of possible strategies.
Unfortunately, the results of clinical trials that are most
often published have a low level of evidence. Studies with-
out a control group that are carried out according to a
“before/after” methodology and/or use of historical com-
parisons are not appropriate for drug evaluation because
they are potentially biased [10-13]. The choice of study de-
sign for small clinical trials may be based on the kind of
endpoint and follow-up duration [14,15], but this type of
approach does not allow to take into account the trial’s
aims, the number of patients required to have enough
statistical power, intra- and inter-subject variability, and
the duration and cost of the trial (according to patients,
investigators, and the sponsor) [16]. With this in mind, we
propose a two-stage approach, that includes (i) collecting
and retrospectively analyzing available epidemiological
and RCT databases and (ii) using an in silico modeling
and simulation approach.
Methodological approach
The methodological approach used here comprised of
several steps (Table 2). For a given rare disease, the aim
is to help identify the treatment that seems the most ef-
ficacious out of several potential treatments and further
tested in a phase III clinical trial with an optimal experi-
mental design in patients chosen where necessary based
on specific prognostic and predictive markers. This
process is done by retrospectively analyzing all available
clinical databases and creating in silico (mathematical)
models describing the disease, each treatment effect, and
Table 2 Steps involved in methodological approach
Steps Approaches Methods
Step 1 Use available knowledge Bibliography
(i) Pathophysiology, diagnosis, therapeutics, pharmacology
(ii) Discursive and mathematical models for the disease
(iii) Discursive and mathematical models for the drug effect(s)
Individual epidemiological and RCT databases
(i) Statistical approaches for analysis
(ii) Identify prognostic biomarkers
(iii) Identify N potential drugs (or therapeutic strategies)
for evaluation in phase III RCTs
(iv) Identify predictive biomarkers for these N drugs (e.g. interactions
between patient characteristics and drug efficacy)
(v) Validate drug-disease models
Step 2 Drug-disease modeling for the N treatments identified above Treatment 1: (Disease model + Drug effect model 1)
Treatment i: (Disease model + Drug effect model i)
Treatment N: (Disease model + Drug effect model N)
Step 3 Drug-disease modeling for the N treatments above in
patients whose characteristics may interact with
drug efficacy
Treatment 1: (Disease model + Drug effect model 1) in patients
whose specific characteristics interact with treatment effect 1
Treatment i: (Disease model + Drug effect model i) in patients
whose specific characteristics interact with treatment effect i
Treatment N: (Disease model + Drug effect model N) in patients
whose specific characteristics interact with treatment effect N
Step 4 Experimental RCT design modeling (including orthogonal
approaches) for N conditions above
P experimental designs *N situations
Step 5 Simulate these N*P options Results ordered in terms of potential efficacy, adverse events,
number of needed patients, cost (including trial duration)
Step 6 Identify the most relevant drugs to be evaluated in phase III
RCTs and the RCT design to be used for each of them
Multiple-criteria decision analysis approaches
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populations and according to different study designs
(Figure 1). The results are then ranked, according to po-
tential efficacy, adverse events, number of patients
needed, and the cost and duration of trials (Figure 2).
This will allow selection of the drug(s) among old com-
pounds to be further evaluated in a phase III trial using
the most appropriate study design.
Collection of databases
The first step is to collect data that are as exhaustive as
possible on a given rare disease from existing clinical da-
tabases [17]. The main items used to characterize a data-
base are listed in Table 3. For epidemiological studies,
the highest level of evidence is in patient registries that
are on-going, exhaustive systems of data collection of
patients with the same disease(s) from a geographically-
defined population over an extended period of time.
Patient data registries constitute key instruments support-
ing health service planning, increasing knowledge on
rare diseases, and support research by pooling data. Theobjectives of these databases are to include extensive in-
formation on all forms of a given rare disease grouped
within several main categories. Long-term objectives in-
clude improving disease management and patient care,
targeting preventive measures to lower co-morbidities,
thereby improving the quality of life of patients. Such
epidemiological registries are a basic prerequisite for
obtaining a comprehensive and accurate description of a
rare disease. There is no formal method to conduct an ex-
haustive search for such available databases. As in a meta-
analytic process, such a search should be performed in
computerized and non-computerized databases. Bibliog-
raphies of relevant papers and conference proceedings
have also to be hand searched and experts, drug manufac-
turers, and primary authors must be contacted for infor-
mation on additional existing datasets. The search must
not be limited by language. Contacts with patient associa-
tions are also always necessary. In the field of cystic fibro-
sis (CF), an example of such overview of international
literature from CF registries is given by Salvatore et al.
[18-20] and Buzzetti et al. [21].
Database analysis Prognostic biomarkers 
Predictive biomarkers
Virtual population of 
patients
Disease pathophysiology Disease models including
Prognostic biomarkers
Natural evolution of 
the disease
Drug(s) of interest PK/PD models including
predictive biomarkers
Virtual population of  
patients
Trial design RCT simulation Design performance
INPUT OUTPUT
Figure 1 Flow chart for modeling and simulation approach.
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Retrospective identification and validation of prognostic
biomarkers
A biomarker is considered prognostic when there is an
association between the marker's values at baseline or
changes in the marker over time and a clinical endpoint,
separate from treatment. To be validated, its association
with the clinical endpoint should be repeatedly demon-
strated in independent studies and preferably across a
range of clinical situations. Contrary to common belief,
heterogeneity is more often an asset than a liability from
a statistical point of view. Retrospective studies may be
sufficient for the initial identification and statistical val-
idation of prognostic biomarkers, but the biomarker’s
clinical utility may need to be confirmed in prospective
studies [22].
Retrospective identification of predictive biomarkers
A biomarker is considered predictive if the baseline
value or changes in value over time are shown to predict
the efficacy or toxicity of a treatment when assessed by a
defined clinical endpoint. For a putative predictive bio-
marker to be validated, its ability to predict the effects of
treatment should be repeatedly demonstrated in multiple
studies. The statistical identification of predictive markers
requires data from RCTs that include patients with high
and low levels of the biomarker. Retrospective analyses
may be sufficient to identify candidate predictive bio-
markers and validate them well enough to be incorporated
into trial designs and clinical practice. But prospective
clinical trials may still be needed for definitive evidence
[22]. However, identification of prognostic and predictive
biomarkers with an adequate power requires datasets in-
cluding a sufficient number of patients. This may be notpossible in ‘very rare’ or ‘ultra-rare’ diseases, i.e., diseases
affecting fewer than 20 patients per million of population
(or, one patient per 50,000 people) and most ultra-rare
diseases affect far fewer than this as few as one per million
or less.
Retrospective identification of potential treatments of
interest
Many different methods have been proposed to assess
treatment effects in observational studies [23]. With all
these methods, the main objective is to deal with the po-
tential bias caused by the nonrandomized assignment of
treatments, i.e. confounding [24]. The most frequently
used methods are (i) Observational study designs (historical
controls [25], candidates for treatment, comparing treat-
ments for the same indication, case-crossover and case-
time-control design [26-29], (ii) Data-analytical techniques
(stratification and matching on certain covariates [30],
asymmetric stratification [31], common multivariable stat-
istical techniques (multivariable linear regression, logistic
regression, and cox proportional hazards regression) [32,33]
and propensity score adjustment [34,35], multivariate con-
founder score [36], instrumental variables [37], simultan-
eous equations and two-stage least squares [38].
Disease/drug effect modeling and RCT simulation
Modeling and simulation
A model is the simplified representation of a process or a
system using physical or information technology methods,
logical relationships, or mathematical formulas. A model
generally corresponds to any coherent construction based
on a definite collection of observations and experimental
facts, in short knowledge, about the studied phenomenon.
A simulation predicts output functions by changing the
Figure 2 Modeling of Dornase effect on mucociliary clearance in cystic fibrosis patients: simulation of 7 RCTs experimental designs
and comparative assessment of design performances. 50 patients were included per trial (except N-of-1). (a) Power expressed in %, (b) Variability
(coefficient of variation of results) expressed in %, (c) No. of patients under active treatment, (d) Trial duration expressed in arbitrary units.
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Table 3 Items to be considered for a standardized description of databases/registries
Items Examples
Type of database Registry
Objectives Include extensive information on all forms of a given rare disease grouped within several main categories
Database conception Team composed of clinicians and databank professionals
Recruitment sources Nationwide recruited patients
Inclusion/exclusion criteria Number of variables collected per patient at each visit
Follow-up characteristics: Number of follow-up visits per year for each patient
Main results Launch date
Total number of patients
Median duration of follow-up
Number of centers
Database perpetuation Specific contacts with the coordinating team through e-mail, phone calls and local visits, periodic meetings
with all affiliated centers.
Technical aspects Use of a secured Internet protocol into a safe database through a web interface and specification of the
characteristics of the available export formats
Ergonomic aspects Rolling menus and data entry forms accessible to unskilled users
Cross-linking of registries In order to share and compare data with other similar registries in other nations
Quality control A data manager/technical team should be in charge of quality control, monitoring for data coherence,
absence of duplicates, and transfer of data
Organization/management rules A charter describes general rules relating to organization and rules governing access to data
Data sharing Rules for sharing: for cross-centre studies, the respective centers must agree explicitly to share its
anonymous data with other centers
Confidentiality of patient records All subjects receive a unique study-identification code, which anonymizes the records. Only the registry's
main investigators know the code and are able to link an individual report to an individual patient
Ethical considerations Informed consent characteristics
Funding sources, competing interests To be extensively specified
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studied process.
The main objectives of modeling/simulation have trad-
itionally been to: describe/explain, summarize, predict,
and teach. Another objective of modeling/simulation is
to identify the “key points” of the disease mechanism,
identify the characteristics of patients who respond to
treatment, or even propose biomarkers as potential end-
points [39,40].
The following two approaches are opposed to each
other in modeling, but they are in fact complementary
(i) using real data to determine the structure and param-
eters of the experimental data model (minimization
techniques), (ii) using different models that have already
been published in the scientific literature and putting
them together (the “Lego®-like principle”). Two model
types are traditionally adapted; the phenomenological/
empirical model and the mechanistic model involves
collecting and critically analyzing available knowledge on
the studied problem, choosing biological hypotheses
(simplified hypotheses or ones that replace insufficient
knowledge), designing and writing the discursive model,
setting up equations, determining model parameters,implementing analyzing the model, studying its robust-
ness, and carrying out simulations. During these steps,
the principles of parsimony and reality should always be
respected.
Disease/drug effect modeling
So far, many disease models have been published in the lit-
erature. Their mathematical formulation is mainly based
on ordinary differential equations (ODEs) and/or partial
differential equations (PDEs) and these models often
allow to simulate biomarker evolution during disease de-
velopment [41-43]. Treatment effect modeling is most
often based on pharmacokinetic-pharmacodynamics rela-
tionships and models on this topic are already available
[44]. These models are especially useful for predicting bio-
marker changes after changing the dosage of an adminis-
tered treatment [45,46]. In cystic fibrosis, Smith et al. [47]
reviewed existing mathematical models of the fluid me-
chanics of mucociliary clearance, taking into account
the morphology of the bronchial and tracheal airway
surface liquid and ciliated epithelium, the cilia beat cycle,
beat frequency and metachronal coordination and also the
rheology of the mucous layer. For Dornase alpha, two sub
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scribed by Shak et al. [48] and its differential deposition
after inhalation by Yeh et al. [49].
Randomized controlled trial (RCT) modeling
Potential experimental designs
Because observational studies are not valid alternatives to
RCTs, specific experimental designs for RCTs have been
developed in addition to the parallel-group design (in
which participants are randomized to one of two or more
arms, active control(s), or a placebo) [14,50]. Each design
has its own characteristics and objectives and not all the
designs listed below can be proposed in a given [drug, dis-
ease, endpoint] context [11]. These include crossover, fac-
torial, randomized withdrawal, and early-escape designs.
The crossover design compares two or more treatments
by randomly assigning each participant to receive study
treatments in a different sequence. Once participants fin-
ish a treatment, they are switched to another one. With
the factorial design, two or more treatments are evaluated
simultaneously with the same participant population using
randomization with various treatment combinations.
With the randomized withdrawal design, participants
who respond positively to a study treatment are random-
ized to continue receiving that treatment or receive a pla-
cebo. The early-escape design is another way to minimize
participants’ duration of exposure to a placebo by remov-
ing them from the study if they do not respond to a de-
fined extent.
Single-subject (N-of-1), sequential, and adaptive designs
have been developed for small-size studies. The N-of-1
trial design is a randomized multi-crossover study of an
individual patient’s responses to a set of treatments (usu-
ally two). Treatments are randomly assigned individually
or within paired periods and given applied to the patient.
The patient’s disease status is measured at set time inter-
vals, corresponding to different treatment periods. After
several crossover periods, comparisons are made between
the outcomes obtained for each drug.
The sequential design was created because the single-
stage design can be difficult to implement due to ethical
problems (impossibility of stopping an ongoing trial even
if the early data show a clear difference between treat-
ments) and/or economic reasons (the sample size is some-
times very large). With early termination procedures,
repeated statistical analyses can be performed throughout
the trial recruitment period and stop the trial as soon as
you have enough data, while maintaining a pre-specified
alpha level.
In adaptive design assignment probabilities are skewed
to favor the best-performing treatment in ongoing trials.
The “play-the-winner” rule is the major advantage of the
adaptive design because more patients will be assigned to
the more successful treatment over time. In other possibledesigns (randomized placebo phase, stepped wedge trials)
either the time spent on placebo is minimized or all pa-
tients receive the active treatment at the end of the trial.
This is very important when studying treatments for life-
threatening rare diseases, especially with the ethical issues
involved (i.e. the need to minimize placebo administration
in severe patients).
Orthogonal approaches
In addition to the above mentioned designs, “orthogonal”
or “meta” methods may also be used. With the Bayesian ap-
proach, researchers adapt the trial through information col-
lected during the trial. This makes it possible to run smaller
more informative trials and patients receive better treat-
ment. Collected results can be assessed at any time, with
the possibility of modifying the trial design e.g. one may
slow, stop, or expand accrual; imbalance randomization to
favor better-performing therapies; drop or add treatment
arms; or change the trial population to focus on patient
subsets that respond better to study treatments. Multi-stage
designs and the meta-analytic approach should also be
considered.
Randomized controlled trial (RCT) simulation
Simulation of in silico trials requires mathematical models
of the disease, drug/patient interaction, and the experimen-
tal design [51]. These models often exist already and are
published, but they usually address a specific aspect of the
problem, e.g. pharmacokinetic (PK) and pharmacokinetics/
pharmacodynamics (PK/PD) models in adults for a given
drug, pathophysiology, and disease development (such
as receptor function, biomarker action, and genetic as-
pects). Published models may be found in bibliographic
databases. But additional models may have to be developed
if necessary.
A simulation plan is then set-up with a list of linked
models [45,52]. For a given therapeutic strategy, each simu-
lation model is classified by one of these sub-models:
(i) The input-output (IO) sub-model predicts patient
outcomes. It includes a pathophysiological model of the
disease (if any) and PK/PD drug properties [53]. The
model structure and parameters must be based on existing
data from clinical studies to adequately simulate drug (and
metabolite) concentrations, biomarkers of therapeutic
or toxicological response, or the incidence of a clinical
outcome or adverse event.
(ii) The covariate distribution sub-model describes
patient characteristics and is created using existing patient
databases;
(iii) The execution sub-model describes the character-
istics of experimental designs and protocol deviations
(i.e. either patient-related or investigator-related) [52]. All
protocol deviations are unexpected by nature and only
probabilistic models can be used to simulate them [46].
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effect as the sum of the IO sub-model and execution
sub-model [39,40].
The simulation process is divided into two steps: the
simulation of a virtual population of patients, and the simu-
lation of RCTs using specific experimental designs. Simu-
lation of a virtual population of N virtual patients is
generated and several covariate values are randomly
assigned to each patient: IO sub-model parameters, for
therapeutic and adverse effects, execution sub-model pa-
rameters, and covariates for investigators (center) or pa-
tients (inclusion/exclusion criteria, baseline characteristics
including prognosis and predictive biomarkers). Samples
of patients are then randomly drawn from this population
for inclusion in each clinical trial.
In simulation of RCTs random samples of patients
drawn from the virtual population are included in silico
clinical trials. Random treatment allocation is based on a
series of random-permutation blocks in order to avoid an
imbalance between the treated and control groups for
each trial when appropriate. The diversity of drug-patient
interactions for therapeutic and adverse effects is simu-
lated using the variance of each parameter distribution
of the IO sub-model. Some protocol deviations may be
added to the full model. These are either treatment-related
(e.g. switching to another treatment) or patient-related
(e.g. a missed appointment or definitive dropout). For a
given disease, a given number of virtual trials is independently
simulated for each experimental design.
Analysis of simulation results
Statistical analysis of the results of each RCT
Depending on each study design, different statistical
methods may be used such as parametric and/or non-
parametric tests, hierarchical models, and/or sequential
analysis (e.g. using a triangular test).
Analysis of final results
The final analysis should determine the most relevant
drugs (multiple-criteria decision analysis approaches) and
experimental designs to be evaluated in phase III RCTs.
This analysis would be mostly descriptive. Each situation,
(i.e. trial design and “rare disease-drug” pair) should be
ranked according to the number of times significant result
is attained in each trial. This final hierarchy takes into ac-
count the precision of treatment effect estimations and
trial duration. Figure 2 shows what could be a graphical
representation of the main results of our approach taking
the effect of Dornase alpha in CF patients as an example
and using mucociliary clearance as the main endpoint. Ac-
cording to the trial lists preference, either a high precision
or a high power or a reduced time for patients, investiga-
tors or sponsor can be favored for choosing the most
appropriate design.European Child-Rare-Euro-Simulation (CRESim) Project
The main objective of this ongoing Child-Rare-Euro-
Simulation (CRESim) project is to create a platform (using
cloud computing technology) for performing in silico ex-
periments that assess RCT designs for drug evaluation
in children with rare diseases. This project is funded by
the European Union’s ERA-Net PrioMedChild (Priority
Medicines for Children). For demonstration purposes,
three diseases are studied: Dravet Syndrome (DS) causing
severe myoclonic epilepsy in infancy, cystic fibrosis (CF),
and lymphoblastic lymphoma (LL). An example of prelim-
inary results in CF has been shown in Figure 2.
Future directions
The approach proposed above may be applied to several
different situations by combining three aspects diseases-
drugs-endpoints and could be integrated into a transla-
tional research process. Existing databases could be
analyzed to identify prognostic and predictive biomarkers,
potential treatments, and for the digital validation of
models. This approach could be implemented in a larger
perspective combining different diagnostic strategies.
Lastly, this approach could contribute to the development
of European Medicines Agency guidelines.
Conclusion
We anticipate this approach will be useful for the greater
orphan disease research community and provide funding
organizations and patient advocacy groups with sugges-
tions for the best way forward. In addition to enabling
academic clinical research, strategies such as this may
also help start-up companies obtain funding, as well as
increase the pharmaceutical industry’s commitment to
orphan drug development. However, this proposed in
silico approach for rare diseases would need a final and
consistent validation of the treatment effect using always
an in vivo clinical trial carried out in real patients. Our
approach could be considered as a potential way to fos-
ter reflection on orphan drug development.
Abbreviations
CRESim: Child rare euro simulations; CF: Cystic fibrosis; DV: Dravet syndrome;
IO: Input Output; LL: Lymphoblastic lymphoma; RCTs: Randomized controlled
trials; ODEs: Ordinary differential equations; PDEs: Partial differential
equations; PK/PD: Pharmacokinetic/pharmacodynamic.
Competing interest
The authors declare that they have no competing interests.
Authors’ contributions
All the authors contributed to the conception of this project and the analysis
and interpretation of the trial designs in the setting of the CRESim and
Epi-CRESim project groups. They were all involved in critically revising
the manuscript for important intellectual content and they have all approved
this final version.
Acknowledgements
CRESim was funded by the ERA-NET PRIOMEDCHILD Joint Call in 2010.
Nony et al. Orphanet Journal of Rare Diseases 2014, 9:164 Page 9 of 10
http://www.ojrd.com/content/9/1/164Members of the CRESim Project Group: Leon Aarons; Agathe Bajard;
Clément Ballot; Yves Bertrand; Frank Bretz; Daan Caudri; Charlotte Castellan;
Salma Malik; Sylvie Chabaud; Catherine Cornu; Frank Dufour; Cornelia
Dunger-Baldauf; Jean-Marc Dupont; Roland Fisch; Renzo Guerrini; Behrouz
Kassaï; Patrice Nony; Kayode Ogungbenro; David Pérol; Gérard Pons; Harm
Tiddens; Anna Rosati.
Members of the Epi-CRESim Project Group: Corinne Alberti; Catherine
Chiron; Catherine Cornu, Polina Kurbatova; Rima Nabbout; Patrice Nony;
Vincent Jullien; Pascal Benquet; Fabrice Wendling.
Author details
1CHU Lyon, Service de Pharmacologie Clinique et Essais Thérapeutiques,
Lyon, France. 2University of Lyon 1, UMR 5558, CNRS, Lyon, France. 3Hôpital
Louis Pradel, Centre d’Investigation Clinique, INSERM CIC1407/UMR5558,
Bron, France. 4Unité de Biostatistique et d’Evaluation des Thérapeutiques,
Centre Léon Bérard, Lyon, France. 5Institut Camille Jordan UMR 5208
Université Claude Bernard, Lyon 1, France. 6Service de Pharmacologie
Clinique et Essais Thérapeutiques-HCL, Groupement Hospitalier Est, Hôpital
Cardiovasculaire et Pneumologique Louis Pradel, 28, Avenue du Doyen
Lépine, 69677 Bron Cedex, France.
Received: 2 June 2014 Accepted: 14 October 2014
Reference
1. EURORDIS. What is a rare disease? (http://www.eurordis.org/content/what-
rare-disease) Accessed on: 31 October. 2011.
2. EURORDIS:Rare diseases: understanding this public health priority european
organisation for rare diseases (http://www.eurordis.org/IMG/pdf/princeps_
document-EN.pdf) Accessed on: 17 February. 2013.
3. Friedman LM, Furberg CD, DeMets DL: Fundamentals of Clinical Trials. St
Louis: Mosby-Year Book; 1996.
4. Chalmers I: Why transition from alternation to randomisation in clinical
trials was made. BMJ 1999, 319:1372.
5. Urbach P: The value of randomization and control in clinical trials. Stat Med
1993, 12:1421–1431.
6. Feinstein AR: Current problems and future challenges in randomized
clinical trials. Circulation 1984, 70:767–774.
7. Concato J, Shah N, Horwitz RI: Randomized, controlled trials, observational
studies, and the hierarchy of research designs. N Engl J Med 2000,
342:1887–1892.
8. MacMahon S, Collins R: Reliable assessment of the effects of treatment
on mortality and major morbidity, II: observational studies. Lancet 2001,
357:455–462.
9. McKee M, Britton A, Black N, McPherson K, Sanderson C, Bain C:
Methods in health services research. Interpreting the evidence:
choosing between randomised and non-randomised studies.
BMJ 1999, 319:312–315.
10. Grimes DA, Schulz KF: Bias and causal associations in observational
research. Lancet 2002, 359:248–252.
11. Grimes DA, Schulz KF: Descriptive studies: what they can and cannot do.
Lancet 2002, 359:145–149.
12. Jepsen P, Johnsen SP, Gillman MW, Sorensen HT: Interpretation of
observational studies. Heart 2004, 90:956–960.
13. Spilker B: Guide to clinical Trials. New York: Raven Press; 1991.
14. Cornu C, Kassai B, Fisch R, Chiron C, Alberti C, Guerrini R, Rosati A, Pons G,
Tiddens H, Chabaud S, Caudri D, Ballot C, Kurbatova P, Castellan AC, Bajard
A, Nony P, CRESim & Epi-CRESim Project Groups: Experimental designs for
small randomised clinical trials: an algorithm for choice. Orphanet J Rare
Dis 2013, 8:48.
15. Gupta S, Faughnan ME, Tomlinson GA, Bayoumi AM: A framework for
applying unfamiliar trial designs in studies of rare diseases. J Clin
Epidemiol 2011, 64:1085–1094.
16. Senn S: Cross-over Trials in Clinical Research. Chichester: Wiley; 1993.
17. Nathan N, Taam RA, Epaud R, Delacourt C, Deschildre A, Reix P, Chiron R,
De PU, Brouard J, Fayon M: A national internet-linked based database for
pediatric interstitial lung diseases: the French network. Orphanet J Rare
Dis 2012, 7:40.
18. Salvatore D, Buzzetti R, Baldo E, Forneris MP, Lucidi V, Manunza D,
Marinelli I, Messore B, Neri AS, Raia V, Furnari ML, Mastella G: An
overview of international literature from cystic fibrosis registries 2.Neonatal screening and nutrition/growth. J Cyst Fibros 2010,
9(2):75–83. doi:10.1016/j.jcf.2009.11.002. Epub 2009 Dec 2.
19. Salvatore D, Buzzetti R, Baldo E, Forneris MP, Lucidi V, Manunza D,
Marinelli I, Messore B, Neri AS, Raia V, Furnari ML, Mastella G: An
overview of international literature from cystic fibrosis registries. Part
3. Disease incidence, genotype/phenotype correlation, microbiology,
pregnancy, clinical complications, lung transplantation, and
miscellanea. J Cyst Fibros 2011, 10(2):71–85. doi:10.1016/j.jcf.2010.12.005.
Epub 2011 Jan 22.
20. Salvatore D, Buzzetti R, Baldo E, Furnari ML, Lucidi V, Manunza D,
Marinelli I, Messore B, Neri AS, Raia V, Mastella G: An overview of
international literature from cystic fibrosis registries. Part 4: update
2011. J Cyst Fibros 2012, 11(6):480–493. doi:10.1016/j.jcf.2012.07.005.
Epub 2012 Aug 9.
21. Buzzetti R, Salvatore D, Baldo E, Forneris MP, Lucidi V, Manunza D, Marinelli
I, Messore B, Neri AS, Raia V, Furnari ML, Mastella G: An overview of
international literature from cystic fibrosis registries: 1. Mortality and
survival studies in cystic fibrosis. J Cyst Fibros 2009, 8(4):229–237.
doi:10.1016/j.jcf.2009.04.001. Epub 2009 May 6.
22. Buyse M, Michiels S, Sargent DJ, Grothey A, de GA Matheson A: Integrating
biomarkers in clinical trials. Expert Rev Mol Diagn 2011, 11:171–182.
23. Klungel OH, Martens EP, Psaty BM, Grobbee DE, Sullivan SD, Stricker BH,
de BA Leufkens HG: Methods to assess intended effects of drug
treatment in observational studies are reviewed. J Clin Epidemiol
2004, 57:1223–1231.
24. Rosenbaum PR: Observational Studies. New York: Springer; 2002.
25. Sacks H, Chalmers TC, Smith H Jr: Randomized versus historical controls
for clinical trials. Am J Med 1982, 72:233–240.
26. Greenland S: Confounding and exposure trends in case-crossover and
case-time-control designs. Epidemiology 1996, 7:231–239.
27. Maclure M: The case-crossover design: a method for studying transi-
ent effects on the risk of acute events. Am J Epidemiol 1991,
133:144–153.
28. Suissa S: The case-time-control design. Epidemiology 1995, 6:248–253.
29. Suissa S: The case-time-control design: further assumptions and conditions.
Epidemiology 1998, 9:441–445.
30. Cochran WG: The effectiveness of adjustment by subclassification
in removing bias in observational studies. Biometrics 1968,
24:295–313.
31. Cook EF, Goldman L: Asymmetric stratification. An outline for an efficient
method for controlling confounding in cohort studies. Am J Epidemiol
1988, 127:626–639.
32. Peduzzi P, Concato J, Feinstein AR, Holford TR: Importance of events per
independent variable in proportional hazards regression analysis. II.
Accuracy and precision of regression estimates. J Clin Epidemiol 1995,
48:1503–1510.
33. Peduzzi P, Concato J, Kemper E, Holford TR, Feinstein AR: A simulation
study of the number of events per variable in logistic regression
analysis. J Clin Epidemiol 1996, 49:1373–1379.
34. D'Agostino RB Jr: Propensity score methods for bias reduction in the
comparison of a treatment to a non-randomized control group. Stat Med
1998, 17:2265–2281.
35. Rosenbaum PR, Rubin DB: The central role of the propensity score in
observational studies for causal effects. Biometrika 1983, 70:41–55.
36. Miettinen OS: Stratification by a multivariate confounder score. Am J
Epidemiol 1976, 104:609–620.
37. Newhouse JP, McClellan M: Econometrics in outcomes research:
the use of instrumental variables. Annu Rev Public Health 1998,
19:17–34.
38. Angrist JD, Imbens GW: Two-Stage Least Squares Estimation of Average
Causal Effects in Models with Variable Treatment Intensity. Journal of the
American Statistical Association 1995, 90:431–442.
39. Boissel JP, Cucherat M, Nony P, Chabaud S, Gueyffier F, Wright JM, Lievre M,
Leizorovicz A: New insights on the relation between untreated and
treated outcomes for a given therapy effect model is not necessarily
linear. J Clin Epidemiol 2008, 61:301–307.
40. Boissel JP, Ribba B, Grenier E, Chapuisat G, Dronne MA: Modelling
methodology in physiopathology. Prog Biophys Mol Biol 2008, 97:28–39.
41. Chapuisat G, Dronne MA, Grenier E, Hommel M, Gilquin H, Boissel JP: A
global phenomenological model of ischemic stroke with stress on
spreading depressions. Prog Biophys Mol Biol 2008, 97:4–27.
Nony et al. Orphanet Journal of Rare Diseases 2014, 9:164 Page 10 of 10
http://www.ojrd.com/content/9/1/16442. Dronne MA, Grenier E, Dumont T, Hommel M, Boissel JP: Role of astrocytes
in grey matter during stroke: a modelling approach. Brain Res 2007,
1138:231–242.
43. Ribba B, Saut O, Colin T, Bresch D, Grenier E, Boissel JP: A multiscale
mathematical model of avascular tumor growth to investigate
the therapeutic benefit of anti-invasive agents. J Theor Biol 2006,
243:532–541.
44. Gabreilsson J, Weiner D, Weiner D: Pharmacokinetic and Pharmacodynamic
Data Analysis: Concepts and Applications. Sweden: Swedish Pharmaceutical
Press; 2007.
45. Blesius A, Chabaud S, Cucherat M, Mismetti P, Boissel JP, Nony P:
Compliance-guided therapy: a new insight into the potential role of
clinical pharmacologists. Clin Pharmacokinet 2006, 45:95–104.
46. Nony P, Cucherat M, Boissel JP: Revisiting the effect compartment
through timing errors in drug administration. Trends Pharmacol Sci 1998,
19:49–54.
47. Smith DJ, Gaffney EA, Blake JR: Modelling mucociliary clearance. Respir
Physiol Neurobiol 2008, 163:178–188.
48. Shak S, Capon DJ, Hellmiss R, Marsters SA, Baker CL: Recombinant human
DNase I reduces the viscosity of cystic fibrosis sputum. Proc Natl Acad Sci
U S A 1990, 87:9188–9192.
49. Yeh HC, Schum GM: Models of human lung airways and their application
to inhaled particle deposition. Bull Math Biol 1980, 42:461–480.
50. Evans CH, IIdstad ST: Small Clinical Trials, Issues and Challenges; Committee
on Strategies for Small-Number-Participant Clinical Research Trials, Board on
Health Sciences Policy, Institute of Medicine. Washington D.C: National
Academy Press; 2003.
51. Chabaud S, Girard P, Nony P, Boissel JP: Clinical trial simulation using
therapeutic effect modeling: application to ivabradine efficacy in
patients with angina pectoris. J Pharmacokinet Pharmacodyn 2002,
29:339–363.
52. Bajard A, Chabaud S, Perol D, Boissel JP, Nony P: Revisiting the level of
evidence in randomized controlled clinical trials: A simulation approach.
Contemp Clin Trials 2009, 30:400–410.
53. Nony P, Boissel JP: Use of sensitivity functions to characterise and
compare the forgiveness of drugs. Clin Pharmacokinet 2002, 41:371–380.
doi:10.1186/s13023-014-0164-y
Cite this article as: Nony et al.: A methodological framework for drug
development in rare diseases. Orphanet Journal of Rare Diseases
2014 9:164.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
